0
Pro
66
Against

If the drug doesn’t shrink your belly fat by at least 8%, it won’t make your fat look healthier on scans — you have to respond to the drug for this benefit.

Scientific Claim

In people living with HIV (PWH) with central adiposity, tesamorelin treatment for 26 weeks does not improve fat density in non-responders, as placebo-treated participants showed no significant change in VAT or SAT density.

Original Statement

Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001].

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The claim is directly supported by the placebo group data showing no significant change. Language is precise and avoids overgeneralization.

Evidence from Studies

Supporting (0)

0
No supporting evidence found

Contradicting (1)

66

The study found that tesamorelin improved fat quality in people who lost belly fat, but it didn’t even look at people who didn’t lose fat — so we can’t say whether it helped or didn’t help them.